Stéphane Saubadu

Efficacy and Safety of Lixisenatide Once-Daily Morning or Evening Injections in Type 2 Diabetes Inadequately Controlled on Metformin (GetGoal-M)

Bo Åhrén, Aniceto Leguizamo Dimas, P. Miossec et al. · Diabetes Care · 2013 · 171 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +15

Inhibition of CD40L with Frexalimab in Multiple Sclerosis

Patrick Vermersch, Cristina Granziera, Yang Mao‐Draayer et al. · New England Journal of Medicine · 2024 · 85 citations

Life Sciences, Neurology, Pharmacotherapy +15

Safety and efficacy of teriflunomide in paediatric multiple sclerosis (TERIKIDS): a multicentre, double-blind, phase 3, randomised, placebo-controlled trial

Tanuja Chitnis, Brenda Banwell, Ludwig Kappos et al. · The Lancet Neurology · 2021 · 81 citations

Medicine, Neurology, Pediatrics +12

Safety, Pharmacokinetics, and Pharmacodynamics of Oral Venglustat in Patients with Parkinson’s Disease and a GBA Mutation: Results from Part 1 of the Randomized, Double-Blinded, Placebo-Controlled MOVES-PD Trial

Michel Peterschmitt, Hidemoto Saiki, Taku Hatano et al. · Journal of Parkinson s Disease · 2021 · 61 citations · Full text

Medicine, Neurology, Pharmacology +17

Safety, tolerability and pharmacokinetics of oral venglustat in Parkinson disease patients with a GBA mutation

Michel Peterschmitt, Thomas Gasser, Stuart Isaacson et al. · Molecular Genetics and Metabolism · 2019 · 18 citations

Medicine, Pharmacokinetics, Pharmacology +14